Free Trial
→ How to play the Biggest IPO in stock market history! (From InvestPub) (Ad)tc pixel Free BIAF Stock Alerts

bioAffinity Technologies (BIAF) Competitors

bioAffinity Technologies logo
$1.37 -0.11 (-7.43%)
Closing price 06/15/2026 04:00 PM Eastern
Extended Trading
$1.41 +0.04 (+2.63%)
As of 06/15/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BIAF vs. PMEC, CAST, GRNQ, DGNX, and JOB

Should you buy bioAffinity Technologies stock or one of its competitors? MarketBeat compares bioAffinity Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with bioAffinity Technologies include Primech (PMEC), FreeCast (Direct Listing) (CAST), Greenpro Capital (GRNQ), Diginex (DGNX), and GEE Group (JOB). These companies are all part of the "business services" industry.

How does bioAffinity Technologies compare to Primech?

Primech (NASDAQ:PMEC) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Primech had 3 more articles in the media than bioAffinity Technologies. MarketBeat recorded 4 mentions for Primech and 1 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 1.27 beat Primech's score of 0.88 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Primech Positive
bioAffinity Technologies Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Primech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Primech has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Primech has higher revenue and earnings than bioAffinity Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Primech$74.35M0.33-$1.94MN/AN/A
bioAffinity Technologies$6.16M1.01-$14.91M-$11.77N/A

88.1% of Primech shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Primech has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. Primech's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
PrimechN/A N/A N/A
bioAffinity Technologies -280.53%-285.75%-143.71%

Summary

Primech beats bioAffinity Technologies on 8 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to FreeCast (Direct Listing)?

bioAffinity Technologies (NASDAQ:BIAF) and FreeCast (Direct Listing) (NASDAQ:CAST) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 0.0% of FreeCast (Direct Listing) shares are owned by institutional investors. 2.7% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 17.5% of FreeCast (Direct Listing) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

FreeCast (Direct Listing) has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. FreeCast (Direct Listing)'s return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
bioAffinity Technologies-280.53% -285.75% -143.71%
FreeCast (Direct Listing) N/A N/A N/A

FreeCast (Direct Listing) has a consensus price target of $6.00, suggesting a potential upside of 60.00%. Given FreeCast (Direct Listing)'s stronger consensus rating and higher probable upside, analysts clearly believe FreeCast (Direct Listing) is more favorable than bioAffinity Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
FreeCast (Direct Listing)
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, FreeCast (Direct Listing) had 23 more articles in the media than bioAffinity Technologies. MarketBeat recorded 24 mentions for FreeCast (Direct Listing) and 1 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 1.27 beat FreeCast (Direct Listing)'s score of 0.19 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Positive
FreeCast (Direct Listing) Neutral

FreeCast (Direct Listing) has lower revenue, but higher earnings than bioAffinity Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$6.16M1.01-$14.91M-$11.77N/A
FreeCast (Direct Listing)$565.17K274.31N/AN/AN/A

Summary

FreeCast (Direct Listing) beats bioAffinity Technologies on 9 of the 12 factors compared between the two stocks.

How does bioAffinity Technologies compare to Greenpro Capital?

Greenpro Capital (NASDAQ:GRNQ) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Greenpro Capital has a net margin of -153.32% compared to bioAffinity Technologies' net margin of -280.53%. Greenpro Capital's return on equity of -31.13% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Greenpro Capital-153.32% -31.13% -25.47%
bioAffinity Technologies -280.53%-285.75%-143.71%

In the previous week, Greenpro Capital and Greenpro Capital both had 1 articles in the media. bioAffinity Technologies' average media sentiment score of 1.27 beat Greenpro Capital's score of 0.93 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Greenpro Capital Positive
bioAffinity Technologies Positive

Greenpro Capital has higher earnings, but lower revenue than bioAffinity Technologies. Greenpro Capital is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenpro Capital$2.07M12.06-$2.98M-$0.39N/A
bioAffinity Technologies$6.16M1.01-$14.91M-$11.77N/A

Greenpro Capital has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.33, suggesting that its stock price is 233% less volatile than the broader market.

0.9% of Greenpro Capital shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 39.7% of Greenpro Capital shares are owned by company insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Greenpro Capital
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Greenpro Capital beats bioAffinity Technologies on 8 of the 12 factors compared between the two stocks.

How does bioAffinity Technologies compare to Diginex?

Diginex (NASDAQ:DGNX) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

1.6% of bioAffinity Technologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diginex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Diginex had 1 more articles in the media than bioAffinity Technologies. MarketBeat recorded 2 mentions for Diginex and 1 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 1.27 beat Diginex's score of 0.94 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Diginex Positive
bioAffinity Technologies Positive

Diginex has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. Diginex's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DiginexN/A N/A N/A
bioAffinity Technologies -280.53%-285.75%-143.71%

Diginex has a beta of -2.74, indicating that its stock price is 374% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Diginex has higher earnings, but lower revenue than bioAffinity Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diginex$2.04M12.50-$5.21MN/AN/A
bioAffinity Technologies$6.16M1.01-$14.91M-$11.77N/A

Summary

Diginex beats bioAffinity Technologies on 6 of the 11 factors compared between the two stocks.

How does bioAffinity Technologies compare to GEE Group?

GEE Group (NYSE:JOB) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, GEE Group and GEE Group both had 1 articles in the media. bioAffinity Technologies' average media sentiment score of 1.27 beat GEE Group's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
GEE Group Neutral
bioAffinity Technologies Positive

30.4% of GEE Group shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 17.0% of GEE Group shares are owned by insiders. Comparatively, 2.7% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GEE Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
bioAffinity Technologies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

bioAffinity Technologies has lower revenue, but higher earnings than GEE Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GEE Group$87.98M0.29-$24.10MN/AN/A
bioAffinity Technologies$6.16M1.01-$14.91M-$11.77N/A

GEE Group has a net margin of -20.77% compared to bioAffinity Technologies' net margin of -280.53%. GEE Group's return on equity of -7.66% beat bioAffinity Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
GEE Group-20.77% -7.66% -6.84%
bioAffinity Technologies -280.53%-285.75%-143.71%

GEE Group has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, bioAffinity Technologies has a beta of -1.33, indicating that its stock price is 233% less volatile than the broader market.

Summary

GEE Group beats bioAffinity Technologies on 7 of the 12 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIAF vs. The Competition

Export
MetricbioAffinity TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.71M$3.40B$6.74B$12.07B
Dividend YieldN/A2.25%2.67%5.66%
P/E Ratio-0.1219.7523.9024.57
Price / Sales1.01311.18511.88141.49
Price / CashN/A53.6127.4837.92
Price / Book0.858.0810.476.78
Net Income-$14.91M$23.89M$3.56B$337.32M
7 Day Performance-9.27%1.74%0.66%2.20%
1 Month Performance-27.13%0.18%1.90%4.06%
1 Year Performance-82.58%45.04%24.86%29.91%

bioAffinity Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIAF
bioAffinity Technologies
0.8924 of 5 stars		$1.37
-7.4%		N/A-83.4%$6.71M$6.16MN/A10
PMEC
Primech
0.7469 of 5 stars		$0.70
+20.7%		N/A-37.3%$26.89M$74.35MN/A2,806
CAST
FreeCast (Direct Listing)
4.0941 of 5 stars		$0.65
-5.7%		$6.00
+827.9%		N/A$26.73M$565.17KN/A48
GRNQ
Greenpro Capital
1.1218 of 5 stars		$1.48
-2.0%		N/A-19.0%$26.68M$2.07MN/A60
DGNX
Diginex
0.6466 of 5 stars		$1.03
+3.7%		N/A-98.2%$26.00M$2.04MN/A21

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BIAF) was last updated on 6/16/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
The Next Qualcomm
Porter Stansberry recommended Qualcomm in 1999 at $4 a share - it climbed more than 5,000%. He found the same ...
Porter & Company | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel